Modification of alternative splicing pathways as a potential approach to chemotherapy

Pharmacology and Therapeutics

Volumn 85, Issue 3, 2000, Pages 237-243

  Mercatante, Danielle ^a   Kole, Ryszard ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Alternative splicing; Antisense oligonucleotides; Cancer chemotherapy; Genetic disorders; RNA splicing

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CASPASE 2; CATHEPSIN B; HERMES ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P73;

ALTERNATIVE RNA SPLICING; BETA THALASSEMIA; CANCER; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CYSTIC FIBROSIS; GENETIC DISORDER; HUMAN; MUSCULAR DYSTROPHY; MUTATION; NEPHROBLASTOMA; PRIORITY JOURNAL; RNA SPLICING; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA-THALASSEMIA; CYSTIC FIBROSIS; DRUG DESIGN; GENES, TUMOR SUPPRESSOR; HUMANS; MUSCULAR DYSTROPHIES; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENES; RNA, MESSENGER;

EID: 0034065833     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(99)00067-4     Document Type: Conference Paper

References (51)

1. Adams J.M., Cory S. The Bcl-2 protein family. arbiters of cell survival Science. 281:1998;1322-1326.
2. Apte S.S., Mattei M.G., Olsen B.R. Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta. Genomics. 26:1995;592-594.
3. Bieche I., Lidereau R. Increased level of exon 12 alternatively spliced BRCA2 transcripts in tumor breast tissue compared with normal tissue. Cancer Res. 59:1999;2546-2550.
4. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nunez G., Thompson C.B. Bcl-x, a bcl-2 related gene that functions as a dominant regulator or apoptotic cell death. Cell. 74:1993;597-608.
5. Buchholz T.A., Weil M.M., Story M.D., Strom E.A., Brock W.A., McNeese M.C. Tumor suppressor genes and breast cancer. Radiat Oncol Invest. 7:1999;55-65.
6. Davies R.C., Calvo C., Bratt E., Larsson S., Lamond A.I., Hastie N.D. WT1 interacts with the splicing factor U2AF65 in an isoform dependent manner and can be incorporated into spliceosomes. Genes Dev. 12:1998;3217-3225.
7. Davies R., Moore A., Schedl A., Bratt E., Miyahawa K., Ladomery M., Miles C., Menke A., van Heyningen V., Hastie N. Multiple roles for the Wilms' tumor suppressor, WT1. Cancer Res. 59:1999;1747-1751.
8. DiPaola R.S., Aisner J. Overcoming bcl-2 and p53 mediated resistance in prostate cancer. Semin Oncol. 26:1999;112-116.
9. Fiche M., Avet-Loiseau H., Heymann M.F., Moussaly F., Digabel C., Joubert M., Classe J.M., Dravet F., Fumoleau P., Ross J., Maugard C.M. Genetic alterations in early-onset invasive breast carcinomas. correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype Int J Cancer. 84:1999;511-515.
10. Friedman K.J., Kole J., Cohn J.A., Knowles M.R., Silverman L.M., Kole R. Correction of aberrant splicing of CFTR gene by antisense oligonucleotides. J Biol Chem. 274:1999;36193-36199.
11. Fujimura M., Kasahara K., Shirasaki H., Heki U., Iwasa K., Ueda A., Matsuda T. Up-regulation of ICH-1L protein by thromboxane A2 antagonists enhances cisplatin-induced apoptosis in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 125:1999;389-394.
12. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., Matzku S., Wenzel A., Ponta H., Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:1991;13-24.
13. Han J.S., Nunez G., Wicha M.S., Clarke M.F. Targeting cancer cell death with a bcl-XS adenovirus. Springer Semin Immunopathol. 19:1998;279-288.
14. Harn H.J., Ho L.I., Shyu R.Y., Yuan J.S., Lin F.G., Young T.H., Liu C.A., Tang H.S., Lee W.H. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol. 22:1996;107-110.
15. Herrera-Gayol A., Jothy S. Adhesion proteins in the biology of breast cancer. contribution of CD44 Exp Mol Pathol. 66:1999;149-156.
16. Hofmann M., Ruddy W., Zoller M., Tolg C., Ponta H., Herrlich P., Gunthert U. CD44 splice variants confer metastatic behavior in rats. homologous sequences are expressed in human tumor cell lines Cancer Res. 51:1991;5292-5297.
17. Hsieh H.-F., Yu J.-C., Ho L.-I., Chiu S.-C., Harn H.-J. Molecular studies into the role of CD44 variants in metastasis in gastric cancer. J Clin Pathol Mol Pathol. 52:1999;25-28.
18. Ito T., Fujieda S., Tsuzuki H., Sunaga H., Fan G., Sugimoto C., Fukuda M., Saito H. Decreased expression of bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Lett. 140:1999;81-91.
19. Jiang Z.H., Wu J.Y. Alternative splicing and programmed cell death. Proc Soc Exp Biol Med. 220:1999;64-72.
20. Kaelin W.G. Jr. The emerging p53 gene family. J Natl Cancer Inst. 91:1999;594-598.
21. Keppler D., Sloane B.F. Cathepsin B. multiple enzyme forms from a single gene and their relation to cancer Enzyme Protein. 49:1996;94-105.
22. Ko J.K., Prives C. P53. puzzle and paradigm Genes Dev. 10:1996;1054-1072.
23. Kole R. Modification of pre-mRNA splicing by antisense oligonucleotides. Stein C.A., Krieg A.M. Applied Antisense Oligonucleotide Technology. 1998;451-469 Willey-Liss, Inc, New York.
24. Koopman G., Heider K.H., Horst E., Adolf G.R., van den Berg F., Ponta H., Herrlich P., Pals S.T. Activated human lymphocytes and aggressive non-Hodgkin's lymphoma express a homologue of the rat metastasis-associated variant of CD44. J Exp Med. 177:1993;897-904.
25. Krawczak M., Reiss J., Cooper D.N. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes. causes and consequences Hum Genet. 90:1992;41-54.
26. Kumar R., Mandal M., Lipton A., Harvey H., Thompson C.B. Overexpression of HER2 modulates Bcl-2, Bcl-xl, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res. 2:1996;1215-1219.
27. Kume T., Oshima K., Shinohara T., Takeo H., Yamashita Y., Shirakusa T., Kikuchi M. Low rate of apoptosis and overexpression of bcl-2 in Epstein Barr virus associated gastric carcinoma. Histopathology. 34:1999;502-509.
28. Lewis J., Yang B., Kim R., Sierakowska H., Kole R., Smithies O., Maeda N. A common human beta globin splicing mutation modeled in mice. Blood. 91:1998;2152-2156.
29. Menke A.L., Van der Eb A.J., Jochemsen A.G. The Wilms' tumor gene. oncogene or tumor suppressor gene? Int Rev Cytol. 181:1998;151-212.
30. Minn A.J., Boise L.H., Thompson C.B. Bcl-x(S) antagonizes the protective effects of Bcl-x(L). J Biol Chem. 71:1996;6306-6312.
31. Moorewood K., Salpekar A., Ivins S.M., Hall J., Powlesland R.M., Brown K.W., Malik K. Transactivation of the WT1 antisense promoter is unique to the WT1[+/-] isoform. FEBS Lett. 456:1999;131-136.
32. O'Connor L., Strasser A., O'Reilly L.A., Hausmann G., Adams J.M., Cory S., Huang D.C.S. Bim. a novel member of the Bcl-2 family that promotes apoptosis EMBO J. 17:1998;384-395.
33. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
34. Pritchard-Jones K. The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pediatr Nephrol. 13:1999;620-625.
35. Rochaix P., Krajewski S., Reed J.C., Bonnet F., Voigt J.J., Brousset P. In vivo patterns of BCl-2 family protein expression in breast carcinomas in relations to apoptosis. J Pathol. 187:1999;410-415.
36. Ruberti G., Cascino I., Papoff G., Eramo A. Fas splicing, variants and their effect on apoptosis. Adv Exp Med Biol. 406:1996;125-134.
37. Schmajuk G.H., Sierakowska H., Kole R. Effects of oligonucleotide backbones on cellular uptake and antisense modification of splicing pathways. J Biol Chem. 274:1999;1783-1789.
38. Schreiber G., Pitterle D., Kim Y.C., Bepler G. Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung. Anticancer Res. 19:1999;1109-1115.
39. Sierakowska H., Sambade M.J., Agrawal S., Kole R. Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA. 93:1996;12840-12844.
40. Sierakowska H., Gorman L., Kang S.H., Kole R. Antisense oligonucleotides and RNAs as modulators of pre-mRNA splicing. Methods Enzymol. 313:1999;506-521.
41. Sneath R.J., Mangham D.C. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol. 51:1998;191-200.
42. Sumantran V.N., Ealovega M.W., Nunez G., Clarke M.F., Wicha M.S. Overexpression of Bcl-xS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 55:1995;2507-2510.
43. Tsujimoto Y., Croce C.M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA. 83:1986;5214-5218.
44. Weijzen S., Velders M.P., Kast W.M. Modulation of the immune response and tumor growth by activated Ras. Leukemia. 13:1999;502-513.
45. Wiechen K., Karaaslan S., Dietel M. Involvement of the c-erbB-2 oncogene product in the egf-induced cell motility of sk-ov-3 ovarian cancer cells. Int J Cancer. 83:1999;409-414.
46. Wilton S.D., Lloyd F., Carville K., Fletcher S., Honeyman K., Agrawal S., Kole R. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord. 9:1999;330-338.
47. Xerri L., Hassoun J., Devilard E., Birnbaum D., Birg F. Bcl-x and the apoptotic machinery of lymphoma cells. Leuk Lymphoma. 28:1998;451-458.
48. Yang X., Lippman M.E. BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat. 54:1999;1-10.
49. Zhang W.G., Ma L.P., Wang S.W., Zhang Z.Y., Cao G.D. Antisense bcl-2 retrovirus vector increases the sensitivity of a human gastric adenocarcinoma cell line to photodynamic therapy. Photochem Photobiol. 69:1999;582-586.
50. Zhang W.W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6:1999;113-138.
51. Zhou M., Demo S.D., McClure T.N., Crea R., Bitler C.M. A novel splice variant of the cell death-promoting protein Bax. J Biol Chem. 273:1998;11930-11936.